Small molecular inhibitors of STAT3 or JAK2 phosphorylation rescued the anemic phenotype, suggesting that STAT3 and JAK2 could be therapeutic targets for DBA treatment. The gene discussed is STAT3; the disease is Diamond-Blackfan anemia.